| Detected | Trial | Change |
|---|---|---|
| 2026-06-04 | NCT04753879 Multi-agent Low Dose Chemotherapy GAX-CI Followed by Olaparib and Pembro in Metastatic… |
date change Primary completion moved earlier: 2026-12-01 -> 2026-07-01 |
| 2026-06-04 | NCT04753879 Multi-agent Low Dose Chemotherapy GAX-CI Followed by Olaparib and Pembro in Metastatic… |
date change Completion moved earlier: 2029-12-01 -> 2026-07-01 |
| 2026-05-30 | NCT07375992 Music Therapy in Newly Diagnosed Glioblastoma After Chemoradiation Therapy (MELODY-GBM) |
Recruitment opened |
| 2026-05-23 | NCT07140315 DK222 Study at Hopkins |
date change Primary completion pushed: 2027-05-01 -> 2027-07-01 |
| 2026-05-23 | NCT07140315 DK222 Study at Hopkins |
date change Completion pushed: 2027-05-01 -> 2027-07-01 |
| NCT ID | Title | Condition | Status |
|---|---|---|---|
| Phase 2 | |||
| NCT05656235 | Renal Retention in High Grade Upper Tract Urothelial Cancer | High Grade Urothelial Carcinoma | Recruiting |
| NCT06059118 | Difluoromethylornithine and High Dose Testosterone With Enzalutamide in Metastatic… | Prostate Cancer | Recruiting |
| NCT04704505 | Bipolar Androgen Therapy (BAT) and Radium-223 (RAD) in Metastatic Castration-resistant… | Prostate Adenocarcinoma | Recruiting |
| NCT06616597 | Trial Targeting Gut Bacterial Androgen Production to Reverse Therapeutic Resistance to… | Prostate Cancer (Adenocarcinoma) | Recruiting |
| NCT04988074 | Trial of Cemiplimab, or Cemip-Chemo Followed by Biomarker-guided Treatment for Pts w/HPV… | HPV-Related Squamous Cell Carcinoma | Recruiting |
| NCT05977907 | Neoadjuvant Pembrolizumab and IO102-103 for Squamous Cell Carcinoma of the Head and Neck… | Head and Neck Squamous Cell Carcinoma | Recruiting |
| NCT07142551 | Supraphysiologic Testosterone Priming Induces Darolutamide Extended Response | Metastatic Castration-resistant Prostate Cancer | Recruiting |
| NCT01804634 | Reduced Intensity Haploidentical BMT for High Risk Solid Tumors | Refractory and/or Relapsed Metastatic Solid Tumors | Recruiting |
| NCT03786796 | Study of Olaparib in Metastatic Renal Cell Carcinoma Patients With DNA Repair Gene… | Renal Cell Carcinoma | Recruiting |
| NCT06376669 | Stereotactic Body Proton Therapy for Treatment of Primary Renal Cell Carcinoma | Renal Cell Carcinoma | Recruiting |
| NCT04363164 | Sequential Testosterone and Enzalutamide Prevents Unfavorable Progression | Castration Resistant Metastatic Prostate Cancer | Recruiting |
| NCT07209189 | Neoadjuvant Chemotherapy and Programmed Cell Death Protein 1(PD-1) Inhibition for Head… | Head and Neck Cancer | Recruiting |
| NCT03521830 | Nivolumab Alone or Plus Relatlimab or Ipilimumab for Patients With Locally-Advanced… | Basal Cell Carcinoma | Recruiting |
| NCT06941857 | NC410 and FOLFIRINOX in Combination With Nivolumab With or Without Ipilimumab in Patients… | Pancreatic Cancer | Recruiting |
| NCT06205836 | Cemiplimab With or Without Fianlimab to Treat Older Patients With Localized or Locally… | Colorectal Cancer | Recruiting |
| NCT00616967 | Carboplatin and Nab-Paclitaxel With or Without Vorinostat in Treating Women With Newly… | Breast Cancer | Active, Not Recruiting |
| NCT03607890 | Study of Nivolumab and Relatlimab in Advanced Mismatch Repair Deficient Cancers Resistant… | Refractory MSI - H Solid Tumors Prior of PD-(L) 1 Therapy | Active, Not Recruiting |
| NCT03573648 | Neoadjuvant Endocrine Therapy, Palbociclib, Avelumab in Estrogen Receptor Positive Breast… | Breast Cancer | Active, Not Recruiting |
| NCT03471650 | Study of PSMA-targeted 18F-DCFPyL PET/CT for the Detection of Clinically Significant… | Prostate Cancer | Active, Not Recruiting |
| NCT02845323 | Neoadjuvant Nivolumab With and Without Urelumab in Cisplatin-Ineligible or… | Urothelial Carcinoma | Active, Not Recruiting |
| NCT07550517 | PSMA-High: EBRT/ PSMA617/ ADT vs. EBRT/ ADT | High-Risk Localized Prostate Cancer | Not Yet Recruiting |
| NCT07281768 | Capecitabine/Oxaliplatin Chemotherapy and Cemiplimab With or Without Fianlimab or… | Colorectal Cancer | Not Yet Recruiting |
| NCT03047135 | Olaparib in Men With High-Risk Biochemically-Recurrent Prostate Cancer Following Radical… | Prostate | Active, Not Recruiting |
| NCT07580339 | Combining DCSZ11 With Radiation and Chemotherapy as Neoadjuvant Treatment for pMMR… | Rectal Cancer | Not Yet Recruiting |
| NCT04848116 | Neoadjuvant Targeting of Myeloid Cell Populations in Combination With Nivolumab in Head &… | Head and Neck Squamous Cell Carcinoma | Active, Not Recruiting |